Douglas G. Cole
Founder & Independent Chairman of the BoardDr. Douglas G. Cole, also known as Doug, M.D., is Co-Founder & Director of Repertoire Immune Medicines, Inc. Dr. Cole serves as the President, Director & Founder at Vesalius Therapeutics Inc. He serves as Director at Cygnal Therapeutics, Inc. He is the Co-Founder and Chairman of Harbinger Health. He serves as Director at KSQ Therapeutics, Inc and serves as its Chairman since 2023. He serves as an Independent Director of Foghorn Therapeutics Inc. since October 2015 and also serves as an Independent Chairman of the Board. He is Co-Founder of Repertoire Immune Medicines, Inc. and serves as its Director and was its Chairman until February 2025. He serves as Director at Harbinger Health, Inc. He is Founder of Foghorn Therapeutics Inc. Dr. Cole serves as Managing Partner & General Partner at Flagship Pioneering. Earlier he was Managing Partner at the firm since joining the firm in 2001, where he focuses on life science investments. He served as the Chairman of the Board at Sigilon Therapeutics, Inc. until August 11, 2023 and served as its Director since 2015 until August 11, 2023. He served as Independent Director of Sana Biotechnology, Inc. since April 2020 until June 05, 2025. He serves as Chairman at Inzen Therapeutics, Inc. He served as Chief Executive Officer of Ensemble Therapeutics Corporation. He co-founded and served as an Acting Chief Executive Officer at Ensemble Discovery Corp. He served as Venture Partner at NewcoGen Group. In 1997, Dr. Cole served as a Program Executive at Vertex Pharmaceuticals, Inc. where he led a multidisciplinary program that conducted preclinical development through Phase II studies in neuronal protection and repair. In 1996, he was the Medical Director at Cytotherapeutics, overseeing varies research and clinical activities related to its cell-based therapeutic technologies. In 1992, Dr. Cole was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. He was instrumental in the establishment of a research program investigating neurotransmitter-signaling events in neuron psychiatric disorders with the support of the NIH and several non-profit research foundations. He served at StemCells Inc. He was a Director of Quanterix Corp. from June 2007 until July 26, 2019. He served as Independent Director of Denali Therapeutics Inc. since May 2015 until August 7, 2023. He serves as Director at Ensemble Therapeutics Corporation, Ensemble Discovery. He served as an Independent Director of Editas Medicine Inc. since November 2013 until December 2017. He served as a Director of Syros Pharmaceuticals, Inc. since April 11, 2013. He served as a Director of Zalicus Inc. since September 2002. Dr. Cole served as a Director of Receptos, Inc. from November 2009 to June 3, 2014. He served as a Director of Agios Pharmaceuticals, Inc. from December 2007 to January 2, 2017. He served as a Director of Resolvyx Pharmaceuticals, Inc. Selecta Biosciences, Inc. and Seventh Sense Biosystems, Inc. He served as a Director of Moderna Therapeutics. He served as a Director of Avedro, Inc. He served as a Director of Concert Pharmaceuticals, Inc. until January 9, 2014. He served as a Director at Tetraphase Pharmaceuticals, Inc. from August 2006 to October 18, 2013 and AVEO Pharmaceuticals Inc. from February 2006 to June 1, 2011. He served as a Director of CGI Pharmaceuticals, Inc. CombinatoRx and Morphotek. He has significant industrial experience and a strong academic background. He serves as a Director of Torque Therapeutics, Inc. He serves as a Member of the Scientific Advisory Board of the Spinal Muscular Atrophy Foundation and the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics and serves on the Board of Directors of the Birch Rock Camp. He serves as a Member of Scientific Advisory Board at Moderna Therapeutics, Inc. He served as a Member of The Scientific Advisory Board at Massachusetts Life Sciences Center until September 30, 2011. Dr. Cole serves as an Observer on the Board of Directors of Alvine Pharmaceuticals, Inc. Dr. Cole obtained post-graduate training in Medicine at the Johns Hopkins Hospital in Baltimore, Maryland and in Neurology at the Massachusetts General Hospital in Boston, Massachusetts. Dr. Cole holds an M.D. degree from the University of Pennsylvania Perelman School Of Medicine in the year between 1982 to 1986, where he was a Member of Alpha Omega Alpha. He also holds an B.A. Degree, magna cum laude with High Distinction in English at Dartmouth College in the year between 1978 to 1982, where Dr. Cole was a Senior Fellow and a Member of Phi Beta Kappa.
Positions
- Company NameFoghorn Therapeutics Inc.Stock CodeFHTXPositionFounder & Independent Chairman of the Board
